Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 1.00 |
| ▸ | BCL2 | P10415 | 16/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681276 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL31384063 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2946904 | 0.97 | BCL2L1 (0.95) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2949972 | 0.95 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2950813 | 0.94 | BCL2L1 (0.89) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL376333 | 0.93 | BCL2L1 (0.86) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2945317 | 0.91 | BCL2L1 (0.83) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2951513 | 0.90 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL4465505 | 0.90 | BCL2L1 (0.88) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL3953783 | 0.89 | BCL2L1 (0.82) | BCL2L1BCL2ALBBCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | claimed |
| CN-115298180-B | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 日本理化学研究所 | 2025-06-10 | — | — | CN | claimed |
| WO-2024168133-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-08-15 | — | — | WO | claimed |
| EP-3331546-B1 | CXCR4 INHIBITOR FOR THE TREATMENT OF CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2023-10-04 | — | — | EP | claimed |
| EP-3581660-B1 | NICHE TARGETING OF QUIESCENT CANCER STEM CELLS | UNIV CALIFORNIA (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | claimed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | claimed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | claimed |
| CN-114786654-A | Compositions and methods for systemic delivery of Bcl-2 and Bcl-xL antagonists | 密执安大学评议会 | 2022-07-22 | — | — | CN | claimed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | claimed |
| US-12565666-B2 | Methods and compositions for modulating a genome | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260008748-A1 | COMPOUNDS WITH BIGUANIDYL RADICAL AND USES THEREOF | INST CURIE (FR) | 2026-01-08 | — | — | US | disclosed |
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250340907-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2009049841-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885ALB 4718/4885 |
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2L1 6/4885BCL2 4/4885ALB 1830/4885 |
| US-20260008748-A1 | COMPOUNDS WITH BIGUANIDYL RADICAL AND USES THEREOF | CBR3, ROS1, CBR1 | BCL2L1 655/4885BCL2 627/4885ALB 4332/4885 |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885ALB 4753/4885 |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885BCL2 1/4885ALB 34/4885 |
| US-12565666-B2 | Methods and compositions for modulating a genome | RPRD2, ERN2, TPR | BCL2L1 3643/4885BCL2 4777/4885ALB 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.